news
-
7 October 2020Axonics® CEO Raymond W. Cohen Named Ernst & Young Entrepreneur of the Year® 2020 Award Winner for Orange County
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, today announced that Raymond W. Cohen, CEO of Axonics, has been named an Ernst & Young Entrepreneur of the Year 2020 Award winner for the Pacific Southwest, Orange County. The Entrepreneur of the Year program honors entrepreneurial business leaders whose vision fosters innovation, growth and prosperity as they build and sustain successful businesses. The award was announced through the program’s first-ever virtual awards gala on October 6, 2020.
Entrepreneur of the Year is one of the preeminent competitive award programs for entrepreneurs and leaders of high-growth companies. Cohen was selected by an independent panel of judges that includes previous award winners, CEOs, private equity and venture capital investors, and other regional business leaders. The award recognizes entrepreneurial leaders who are excelling in overcoming adversity; financial performance; societal impact and commitment to building a values-based company; innovation; and talent management. This year, entrepreneurs that provided strong support for their communities, employees and customers during the COVID-19 crisis were recognized for their resilience and leadership.
Raymond W. Cohen said, “It is an honor to be named a winner of the EY Entrepreneur of the Year Award. Entrepreneurs are critical to driving innovation and the creation of high quality jobs. Given the pandemic and the millions of unemployed, more than ever before, we need entrepreneurs to lead the way to economic recovery. Leading Axonics since its founding has been a great privilege and I am proud to share this recognition with our exceptional and dedicated employees that are focused on improving the lives of patients suffering from bladder and bowel dysfunction.”
As a Pacific Southwest, Orange County award winner, Cohen is now eligible for consideration for the Entrepreneur of the Year National Awards, to be announced on November 19 during a virtual awards gala. The Entrepreneur of the Year National Award winner will then move on to compete for the EY World Entrepreneur of the Year™ Award in June 2021.
Related
Axonics® Provides Update on Inter Partes Review Proceedings
Axonics® Receives Health Canada Approval of Next Generation Implantable Neurostimulator
Axonics® Reports 2-Year Clinical Results from ARTISAN-SNM Pivotal Study
NICE Recommends Axonics® r-SNM System for Treating Overactive Bladder
Axonics® Reports Second Quarter 2020 Results
Axonics® Announces 2-Year Topline Clinical Results from ARTISAN-SNM Pivotal Study
Axonics® Reports Preliminary Second Quarter 2020 Revenue
Axonics® Receives FDA Approval for 3T Full-Body MRI Scans
Axonics® Reports First Quarter 2020 Results
Axonics® Announces Fourth Quarter and Fiscal 2019 Financial Results
Axonics® Sacral Neuromodulation System Receives Reimbursement Approval in Germany
Axonics® Announces FDA Approval of Enhanced Neurostimulator Programmer
Axonics® Announces Preliminary Fourth Quarter and Full Year 2019 Revenue
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sanford Health Now Implanting Axonics® Sacral Neuromodulation Systems
Axonics® Announces Pricing of Public Offering of Common Stock
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System
Axonics® Announces Second Quarter 2019 Financial Results and Operational Update
Axonics® Announces 1-Year Top-Line Clinical Results from its ARTISAN-SNM Pivotal Study
Axonics® Announces Publication of ARTISAN Clinical Study Results in the Journal of Urology
Axonics® Announces First Quarter 2019 Financial Results and Operational Update
Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update
Axonics® Announces Positive Top-Line Clinical Data from its ARTISAN-SNM Pivotal Study
Axonics® Announces Publication of NICE Briefing
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Axonics® Receives Health Canada Approval for its Sacral Neuromodulation External Trial System
Axonics® Announces Closing of Initial Public Offering of Common Stock
Axonics Modulation Technologies, Inc. Announces Pricing of Initial Public Offering of Common Stock
Axonics® Receives Technology Innovation Award from Medtech Insight
Axonics® Receives CE Mark for its Sacral Neuromodulation External Trial System
Axonics® Completes Enrollment of U.S. FDA Pivotal Study for its Sacral Neuromodulation System
Axonics Announces $40 Million Financing
Axonics® Sacral Neuromodulation System Receives Marketing Approval in Australia
Axonics® Granted Seven New U.S. Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics® Appoints Dr. Karen L. Noblett as Chief Medical Officer
Axonics Announces $20.5 Million Second Closing of its Series C Financing
Axonics Announces $14.5 Million First Close of Series C Financing
Axonics Granted Four U.S. Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics Sacral Neuromodulation System Receives Marketing Approval from Health Canada
Axonics Granted New U.S. Patent Related to its Implantable Neuromodulation Technology
Axonics Sacral Neuromodulation System™ Receives MRI Conditional Labeling
Axonics Announces First Patients Treated in Sacral Neuromodulation Study
Axonics Granted Six U.S. Patents Related to its Implantable Neuromodulation Technology
Axonics Modulation Technologies Announces $38.5 Million Series B Financing